vimarsana.com

Page 9 - காப்புரிமை பெற்றது மருந்து ப்ரைஸஸ் விமர்சனம் பலகை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regulations to lower drug prices in Canada delayed yet again after industry cites COVID-19 concerns

Innovative Medicines Canada / Médicaments novateurs Canada: Delaying Implementation of PMPRB s Regulations an Opportunity to Protect Patient Access to Medicines and Vaccines Says Innovative Medicines Canada

(1) OTTAWA, ON / ACCESSWIRE / December 30, 2020 / Innovative Medicines Canada issued the following statement today in response to news from Health Canada that implementation of the Patented Medicine Prices Review Board s amended Regulations will be delayed to July 1, 2021: We support Health Canada s decision to delay the implementation of the Patented Medicine Prices Review Board s amended Regulations until July 1, 2021. This is good news for Canadian patients concerned about the negative impact the regulations will have on their access to new medicines. The middle of a global pandemic is not the time to implement measures that will distract from the fight against COVID-19. Additionally, and as a majority of stakeholders to the PMPRB consultation processes have consistently indicated, these changes will also have a negative impact on patients access to potentially life-saving medicines and vaccines, and on investments in Canada s vitally important life sciences sector. That is

Canada to delay drug price reforms by six months, industry group says

By Reuters Staff Slideshow ( 2 images ) TORONTO (Reuters) - Canada has delayed the implementation of new drug price rules that had been due to go into effect on Friday by six months, the pharmaceutical industry’s main lobby group said on Wednesday. The pharmaceutical industry has fought the new regime, meant to reduce patented drug prices that are among the highest in the world, for years. “The middle of a global pandemic is not the time to implement measures that will distract from the fight against COVID-19,” said Innovative Medicines Canada (IMC), which represents major drugmakers in Canada. “This delay provides the time and the opportunity for government to work closely with industry, patients and other health system stakeholders on a better path forward.”

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.